Instruction 1(b).

FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

| Washington, | D.C. 20549 |
|-------------|------------|
|-------------|------------|

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| 1. Name and Address of Reporting Person*  FREEMAN KEVIN D  (Last) (First) (Middle)  C/O GALECTIN THERAPEUTICS INC.  4960 PEACHTREE INDUSTRIAL BLVD., STE  240  (Street)  NORCROSS GA 30071  (City) (State) (Zip) |   |    |           |                                   |  | 2. Issuer Name and Ticker or Trading Symbol GALECTIN THERAPEUTICS INC  [GALT]  3. Date of Earliest Transaction (Month/Day/Year)  10/21/2021  4. If Amendment, Date of Original Filed (Month/Day/Year) |                              |       |  |       |                    |   |                                  | S. Relationship of Reporting Person(s) to Issuer (Check all applicable)     X Director 10% Owner     Officer (give title Other (specify below)      6. Individual or Joint/Group Filing (Check Applicable Line)     X Form filed by One Reporting Person     Form filed by More than One Reporting Person |  |   |  |   |                                       |
|--|---|----|-----------|-----------------------------------|--|---|------------------------------|-------|--|-------|--------------------|---|----------------------------------|---|--|---|--|---|---------------------------------------|
| Table I - Non-Derivat  1. Title of Security (Instr. 3)  2. Transacti Date (Month/Day)  |   |    |           | on 2A. Deemed Execution Date,     |  | ate,  | 3.<br>Transa<br>Code (<br>8) | ction | 4. Securities Acquired (A)<br>Disposed Of (D) (Instr. 3,                                       |       |                    | or  | 5. Amou<br>Securitie<br>Benefici | nt of<br>es<br>ally<br>-ollowing  | 6. Ownership<br>Form: Direct<br>(D) or Indirect<br>(I) (Instr. 4)                          |   | 7. Nature of Indirect Beneficial Ownership |   |                                       |
|  |   |    |           |                                   |  |   |                              |       |  | v     | Amount             | (A) or (D)  | Pric                             | е   | Transaction(s) (Instr. 3 and 4)  |   |  |   | (Instr. 4)                            |
| Common Stock 10/2:   |   |    | 10/21/2   | 2021                              |  |   |                              | P     |  | 2,000 | A                  | \$3   | 3.19                             | 38,000  |  | I |  | By a limited liability company controlled by the Reporting Person: Freeman Global Holdings LLC <sup>(1)</sup> |                                       |
| Common Stock   |   |    |           |                                   |  |   |                              |       |  |       |                    |   |                                  | 23  | 469  |   | D  |   |                                       |
| Common   | nmon Stock  |    |           |                                   |  |   |                              |       |  |       |                    |   | 16,00                            |   |  | I | IRA  |   |                                       |
|  |   | Ta | ıble II - |                                   |  |   |                              |       |  |       | osed of, convertib |   |                                  |   | Owne   | d |  |   |                                       |
| 1. Title of<br>Derivative<br>Security<br>(Instr. 3)  | 2.<br>Conversion<br>or Exercise<br>Price of<br>Derivative<br>Security |    | if any    | emed<br>tion Date,<br>n/Day/Year) |  | Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)   |                              |       | 6. Date Exercisable and Expiration Date (Month/Day/Year)  Date Expiration Date Expiration Date |       |                    | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)  Amount or Number of Shares |                                  | tr. DS:(III   | 8. Price of Derivative Security (Instr. 5)  (Instr. 5)  (Instr. 5)  (Instr. 5)  (Instr. 5) |   | e<br>s<br>illy                             | 10.<br>Ownershi<br>Form:<br>Direct (D)<br>or Indirect<br>(I) (Instr. 4  | Beneficial<br>Ownership<br>(Instr. 4) |

## **Explanation of Responses:**

1. Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.

Jack W. Callicutt, by power of <u>attorney</u>

10/21/2021

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.